一名美国癌症高发病人和帕金森病人在上海癌症中心接受中国独家实验药物后稳定下来, A U.S. patient with advanced cancer and Parkinson’s stabilized after receiving an experimental China-only drug at a Shanghai cancer center, with U.S.-trained doctors aiding care.

美国一名患有高级肺癌和帕金森病的病人在美国没有剩余的标准治疗选择,在接受象牙菌-PD1/VEGF双性抗体后稳定下来,该抗体只存在于中国上海的贾辉国际癌症中心。 A U.S. patient with advanced lung cancer and Parkinson’s disease, who had no remaining standard treatment options in the U.S., stabilized after receiving ivonescimab—a PD1/VEGF bispecific antibody only available in China—at Jiahui International Cancer Center in Shanghai. 治疗是在与美国训练有素的肿瘤学家Xuan Linli博士进行视频咨询之后进行的。 The treatment followed a video consultation with Dr. Xuan Linli, a U.S.-trained oncologist. 免疫相关并发症需要ICU护理, 但包括药物主要研究人员在内的多学科团队成功管理了这种情况. Immune-related complications required ICU care, but a multidisciplinary team, including the drug’s principal investigator, successfully managed the condition. Jiahui与马萨诸塞州总医院癌症中心合作,提供国际病人服务,包括远程咨询和旅行支助。 Jiahui, partnered with Massachusetts General Hospital Cancer Center, provided international patient services including remote consultations and travel support. 这一案例凸显了全球对中国肿瘤学进步的日益浓厚的兴趣,因为上海正在成为创新癌症护理的关键枢纽。 The case underscores growing global interest in China’s oncology advances, with Shanghai emerging as a key hub for innovative cancer care.